HemoSonics registered its new QStat Cartridge, an extension of its Quantra Hemostasis System, for CE Mark making it available in Europe and Hong Kong for use in trauma surgery and liver transplant procedures, according to a press release.
“Trauma and liver surgeries pose an enormous risk of acute bleeding,” Timothy J. Fischer, president and CEO of HemoSonics, said in the release. “What makes the new QStat Cartridge unique is its unparalleled ease of use and its innovative coagulation tests for critical injury and liver transplant, including platelet contribution to clot stiffness and clot stability to lysis.”
The QStat Cartridge is a fully sealed, room temperature stable, disposable cartridge with a panel of several viscoelastic coagulation tests including clot time, clot stiffness, fibrinogen contribution to clot stiffness, platelet contribution to clot stiffness, and clot stability to lysis.
The clot stability to lysis test can run for up to 60 minutes, whereas the rest of the tests can produce valid results in 25 minutes or less.
Additionally, the Quantra QStat System — including the QPlus Cartridge for cardiovascular and major orthopedic surgeries — provides analysis of clot stiffness in either the presence or absence of tranexamic acid.